129 related articles for article (PubMed ID: 21388070)
1. Durable complete response of hepatocellular carcinoma after metronomic capecitabine.
Brandi G; de Rosa F; Bolondi L; Agostini V; Di Girolamo S; Nobili E; Biasco G
Tumori; 2010; 96(6):1028-30. PubMed ID: 21388070
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma.
Ballardini P; Marri I; Margutti G; Aliberti C; Benea G; Manfredini R
Tumori; 2010; 96(5):768-70. PubMed ID: 21302626
[TBL] [Abstract][Full Text] [Related]
3. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.
Brandi G; de Rosa F; Agostini V; di Girolamo S; Andreone P; Bolondi L; Serra C; Sama C; Golfieri R; Gramenzi A; Cucchetti A; Pinna AD; Trevisani F; Biasco G;
Oncologist; 2013; 18(12):1256-7. PubMed ID: 24232581
[TBL] [Abstract][Full Text] [Related]
4. Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases.
Brandi G; Venturi M; De Lorenzo S; Garuti F; Frega G; Palloni A; Garajovà I; Abbati F; Saccoccio G; Golfieri R; Pantaleo MA; Barbera MA
Cancer Commun (Lond); 2018 Jun; 38(1):41. PubMed ID: 29941039
[TBL] [Abstract][Full Text] [Related]
5. The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma.
Brandi G; Di Federico A; Rizzo A; De Lorenzo S; Vasuri F; Brocchi S; Golfieri R; Morelli MC; Frega G; Palloni A
Anticancer Drugs; 2022 Jan; 33(1):e781-e783. PubMed ID: 34407053
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine for treatment of advanced hepatocellular carcinoma.
von Delius S; Lersch C; Mayr M; Stock K; Schulte-Frohlinde E; Schmid RM; Eckel F
Hepatogastroenterology; 2007 Dec; 54(80):2310-4. PubMed ID: 18265654
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.
Xia Y; Qiu Y; Li J; Shi L; Wang K; Xi T; Shen F; Yan Z; Wu M
Ann Surg Oncol; 2010 Dec; 17(12):3137-44. PubMed ID: 20602260
[TBL] [Abstract][Full Text] [Related]
8. Acral and palmo-plantar hyperpigmentation in a patient with disseminated hepatocellular carcinoma.
Goyal R; Chalamalasetty SB; Madan K; Paul SB; Arora R; Safaya R; Acharya SK
Indian J Gastroenterol; 2007; 26(6):292-3. PubMed ID: 18431015
[TBL] [Abstract][Full Text] [Related]
9. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Patt YZ; Hassan MM; Aguayo A; Nooka AK; Lozano RD; Curley SA; Vauthey JN; Ellis LM; Schnirer II; Wolff RA; Charnsangavej C; Brown TD
Cancer; 2004 Aug; 101(3):578-86. PubMed ID: 15274071
[TBL] [Abstract][Full Text] [Related]
10. Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma.
McIntosh A; Hagspiel KD; Al-Osaimi AM; Northup P; Caldwell S; Berg C; Angle JF; Argo C; Weiss G; Rich TA
Cancer; 2009 Nov; 115(21):5117-25. PubMed ID: 19642177
[TBL] [Abstract][Full Text] [Related]
11. Safety of capecitabine use in patients with liver dysfunction.
Saif MW; Tejani MA
Clin Adv Hematol Oncol; 2007 Sep; 5(9):730-2; discussion 736. PubMed ID: 17982413
[No Abstract] [Full Text] [Related]
12. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
Finn RS; Zhu AX
Expert Rev Anticancer Ther; 2009 Apr; 9(4):503-9. PubMed ID: 19374603
[TBL] [Abstract][Full Text] [Related]
13. Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
Ang SF; Tan SH; Toh HC; Poon DY; Ong SY; Foo KF; Choo SP
Am J Clin Oncol; 2012 Jun; 35(3):222-7. PubMed ID: 21378539
[TBL] [Abstract][Full Text] [Related]
14. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma.
Wang-Yuan Z; Jiang-Zheng Z; Lu YD; Hao XB; Hong T; Huang F; Lei JH; He ZH; Huang MZ
Int J Hyperthermia; 2016; 32(2):193-8. PubMed ID: 26586093
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine in pretreated metastatic cholangiocarcinoma. A case report and review of the literature.
Koutras AK; Talampuka G; Pagoni N; Thomopoulos KC; Kalliolias G; Kalogeropoulou C; Kalofonos HP
J BUON; 2007; 12(2):281-3. PubMed ID: 17600885
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S
Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129
[TBL] [Abstract][Full Text] [Related]
18. [Successful treatment of an elderly patient with pretreated recurrent breast cancer using low-dose capecitabine].
Honma H
Gan To Kagaku Ryoho; 2006 Dec; 33(13):2045-8. PubMed ID: 17197750
[TBL] [Abstract][Full Text] [Related]
19. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
Boige V; Raoul JL; Pignon JP; Bouché O; Blanc JF; Dahan L; Jouve JL; Dupouy N; Ducreux M;
Br J Cancer; 2007 Oct; 97(7):862-7. PubMed ID: 17876335
[TBL] [Abstract][Full Text] [Related]
20. Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.
Shao YY; Huang CC; Lin SD; Hsu CH; Cheng AL
Clin Cancer Res; 2012 Jul; 18(14):3992-7. PubMed ID: 22623732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
